知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

3239 条记录 (耗时 0.045 秒)

    Compositions containing an active fraction isolated from Lycium barbarum and methods of using the same
    2.
    发明申请
    Compositions containing an active fraction isolated from Lycium barbarum and methods of using the same 有权
    含有从枸杞分离的活性成分的组合物及其使用方法

    公开(公告)号：US20050281902A1

    公开(公告)日：2005-12-22

    申请号：US11123152

    申请日：2005-05-06

    申请人： Kin-Ping Wong ,  Ming-Chung Wong

    发明人： Kin-Ping Wong ,  Ming-Chung Wong

    IPC分类号： A61K20060101 ,  A61K36/815 ,  A61K35/78

    CPC分类号： A61K36/815 ,  A61K2300/00

    摘要： The present invention provides extracts of Lycium barbarum useful for inhibiting, interfering and/or controlling pathological angiogenesis or neovascularization of tissues. The invention also provides a method to inhibit metastasis of cancer of colon, lung, liver, kidney, breast and/or cervix in a subject, comprising administering an effective amount of an extract of Lycium barbarum to the subject.

    摘要翻译： 本发明提供了可用于抑制，干扰和/或控制组织的病理性血管生成或新生血管形成的枸杞提取物。 本发明还提供一种抑制受试者中结肠，肺，肝，肾，乳腺和/或子宫颈癌的转移的方法，其包括给受试者施用有效量的枸杞提取物。

    Inhibition of Egr-1 expression by ppar-gamma agonists and related compositions and methods
    5.
    发明授权
    Inhibition of Egr-1 expression by ppar-gamma agonists and related compositions and methods 有权
    通过ppar-gamma激动剂和相关组合物和方法抑制Egr-1表达

    公开(公告)号：US06972175B2

    公开(公告)日：2005-12-06

    申请号：US10305504

    申请日：2002-11-27

    申请人： David Pinsky ,  Tucker Collins

    发明人： David Pinsky ,  Tucker Collins

    IPC分类号： A61K20060101 ,  A61K31/44 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/53 ,  G01N33/566 ,  G01N33/68

    CPC分类号： G01N33/6875 ,  G01N33/566 ,  G01N2500/20

    摘要： This invention provides methods for determining whether an agent increases PPAR-γ-mediated inhibition of Egr-1 expression. This invention also provides methods for inhibiting the onset of atherosclerosis in a transplanted organ. This invention further provides numerous methods for treating disorders, and/or inhibiting the onset of disorders or disorder-related complications by using PPAR-γ agonists. This invention still further provides related methods for inhibiting cancer metastasis, treating and inhibiting the onset of a heart attack, and treating burn and crush injuries. Finally, this invention provides related articles of manufacture.

    摘要翻译： 本发明提供了用于确定试剂是否增加PPAR-γ介导的Egr-1表达抑制的方法。 本发明还提供抑制移植器官中动脉粥样硬化发作的方法。 本发明进一步提供了许多通过使用PPAR-γ激动剂治疗疾病和/或抑制疾病或病症相关并发症发作的方法。 本发明还进一步提供了抑制癌症转移，治疗和抑制心脏病发作的相关方法，以及治疗烧伤和粉碎性损伤。 最后，本发明提供了相关的制造品。

    Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives
    7.
    发明申请
    Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives 审中-公开
    喷他他他及其前体，类似物和衍生物的合成和制备

    公开(公告)号：US20050267056A1

    公开(公告)日：2005-12-01

    申请号：US10942319

    申请日：2004-09-15

    申请人： Pasit Phiasivongsa ,  Sanjeev Redkar

    发明人： Pasit Phiasivongsa ,  Sanjeev Redkar

    IPC分类号： A61K20060101 ,  A61K31/7056 ,  C07H19/00 ,  C07H19/16 ,  C07H19/22

    CPC分类号： C07H19/00 ,  A61K31/7056 ,  C07H19/16 ,  C07H19/22

    摘要： Methods and compositions are provided for efficiently preparing and manufacturing pentostatin. Also provided are novel precursors of pentostatin, pentostatin analogs and derivatives. In one aspect of the invention, a method is provided for total chemical synthesis of pentostatin via a route of heterocyclic ring expansion. For example, a heterocyclic pharmaceutical intermediate for drugs such as pentostatin, e.g., the diazepinone precursor, can be obtained efficiently through a ring expansion of an O—C—N functionality in a hypoxanthine or 2′-deoxyinosine derivative. The methods and compositions can also be used to synthesize and manufacture heterocyclic compounds other than pentostatin, especially pharmaceutically important heterocyclic compounds.

    摘要翻译： 提供方法和组合物用于有效地制备和制备喷司他丁。 还提供了喷司他丁，喷司他丁类似物和衍生物的新型前体。 在本发明的一个方面，提供了一种通过杂环扩展途径对喷司他丁进行全面化学合成的方法。 例如，可以通过次黄嘌呤或2'-脱氧肌苷衍生物中的O-C-N官能团的环扩展来有效地获得药物例如喷他他汀的杂环药物中间体，例如二氮芥酮前体。 所述方法和组合物也可用于合成和制造除喷他他汀以外的杂环化合物，特别是药学上重要的杂环化合物。

    Cystatin C as an antagonist of TGF-beta and methods related thereto
    8.
    发明申请
    Cystatin C as an antagonist of TGF-beta and methods related thereto 有权
    半胱氨酸蛋白酶抑制剂C作为TGF-β的拮抗剂及其相关方法

    公开(公告)号：US20050267021A1

    公开(公告)日：2005-12-01

    申请号：US10967093

    申请日：2004-10-15

    申请人： William Schiemann

    发明人： William Schiemann

    IPC分类号： A61K20060101 ,  A61K38/00 ,  A61K38/18 ,  C07K14/475 ,  C07K14/81

    CPC分类号： C07K14/8139 ,  A61K38/005

    摘要： Disclosed are Cystatin C (CysC) homologues, including CystC homologues that act as antagonists or inhibitors of transforming growth factor-β (TGF-β). Also disclosed are methods to identify CystC homologues that are antagonists or inhibitors of TGF-β and compositions and therapeutic methods using CystC and homologues thereof to regulate the activity of TGF-β, and TGF-β-mediated tumor malignancy and invasion and other TGF-β-mediated fibrotic or proliferative conditions and diseases.

    摘要翻译： 披露了半胱氨酸蛋白酶抑制剂C（CysC）同系物，包括作为拮抗剂或转化生长因子-β（TGF-β）的抑制剂的CystC同系物。 还公开了鉴定作为TGF-β的拮抗剂或抑制剂的CystC同系物的方法，以及使用CystC及其同源物调节TGF-β的活性和TGF-β介导的肿瘤恶性肿瘤和侵袭和其他TGF- β介导的纤维化或增殖性疾病和疾病。

    Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
    9.
    发明授权
    Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin 有权
    通过局部递送可逆灭活的酸化纤溶酶进行溶栓治疗的方法

    公开(公告)号：US06969515B2

    公开(公告)日：2005-11-29

    申请号：US10280444

    申请日：2002-10-25

    申请人： Gary J. Jesmok ,  Kyle A. Landskroner

    发明人： Gary J. Jesmok ,  Kyle A. Landskroner

    IPC分类号： A61K20060101 ,  A61K38/00 ,  A61K38/48 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  C12N9/68

    CPC分类号： C12N9/6435 ,  A61K9/0019 ,  A61K38/4833 ,  A61K38/484 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  C12Y304/21007

    摘要： Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus. The method is applicable to the dissolution of thrombi in artificial devices, e.g., hemodialysis grafts.

    摘要翻译： 公开了允许使用包含可逆灭活的酸化纤溶酶的纤维蛋白溶解组合物以及将纤溶酶局限性递送至血管性血栓闭塞的溶栓方法。 进一步公开的是一种治疗剂量的基本上不含纤溶酶原激活剂的纤维蛋白溶解组合物给予具有血管性血栓闭塞的人或动物的方法。 纤维蛋白溶解组合物包括基本上不含纤溶酶原激活物的可逆失活的酸化纤溶酶。 公开了将纤维蛋白溶解组合物直接进入或紧邻血栓的血管内导管递送，以使纤维蛋白的全身降解最小化，同时保留针对血栓的最大纤溶酶活性。 该方法适用于血栓在人造装置中的溶解，例如血液透析移植物。